Celgene splashes $150m to buy a stake in BeiGene of China and $263m upfront to get rights to a PD-1 antibody that could catapult the US firmly up the immuno-oncology ladder.
Celgene Corp. has turned to China to expand its immuno-oncology pipeline, buying a stake in BeiGene (Beijing) Co. Ltd. and getting access to its investigational PD-1 inhibitor.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
